Latest Angina pectoris Stories
When given for hours as a continuous dose, the heart medication nitroglycerin backfires -- increasing the severity of subsequent heart attacks.
A Heart and Stroke Foundation study has found that women under age 55 fare worse than their male counterparts following a heart attack – and their health status declines more than that of their male counterparts after one month.
Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid (ASA) to avoid blood clots in patients with acute ischaemia of the cardiac muscle.
Although medication which decreases the risk of angina attacks (chest pain caused by blockage of the arteries that supply the heart), are frequently prescribed in patients who have sustained a myocardial infarction, the possible influence of medication on long-term survival is not known, with the exception of beta-blocking agents, which have been shown to decrease mortality in clinical trials performed 30 years ago.
The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.
New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).
An injection of stem cells into the heart could offer hope to many of the 850,000 Americans whose chest pain doesn't subside even with medicine, angioplasty or surgery.
While depression and anxiety have long been recognised as risk factors for heart disease, there is less certainty over the beneficial effects of a 'positive' psychological state.
DURHAM, N.C., June 29, 2011 /PRNewswire/ -- Micell Technologies, Inc.
SAN DIEGO, June 15, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has received clearance from the Russian Ministry of Health and Social Development to commence a Phase 3 registration study for the Company's Generx(TM) (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.
- An armed gangster.